|
Cedars-Sinai Medical Center |
Barry Stripp |
Research Leadership 12 |
Epithelial progenitors and the stromal niche as therapeutic targets in lung disease |
$4,841,830 |
|
The J. David Gladstone Institutes |
Kevin Parker |
Research Leadership 12 |
Engineering Cardiac Tissue for Regeneration and Drug Development |
$7,480,036 |
|
Stanford University |
Hiromitsu Nakauchi |
Research Leadership 12 |
Generation of functional cells and organs from iPSCs |
$6,228,068 |
|
University of California, Santa Cruz |
Richard Gregory |
Research Leadership 12 |
MicroRNA Regulation in Stem Cells, Development, and Disease |
$5,380,705 |
|
University of California, San Diego |
Eric Ahrens |
Research Leadership 12 |
Molecular Imaging for Stem Cell Science and Clinical Application |
$6,443,455 |
|
Sangamo BioSciences, Inc. |
Fyodor Urnov |
Strategic Partnership II |
A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells |
$6 |
|
Capricor, Inc |
Rachel Smith |
Disease Team Therapy Development - Research |
Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction |
$19,782,136 |
|
University of California, Los Angeles |
Stanley Nelson |
Early Translational from Disease Team Conversion |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$6,000,000 |
|
Stanford University |
Michael Longaker |
Training Grant I-1 |
Stanford CIRM Training Program |
$3,733,707 |
|
University of California, San Francisco |
Susan Fisher |
Training Grant I-1 |
Training Grant I |
$3,620,652 |
|
University of California, San Diego |
Lawrence Goldstein |
Training Grant I-1 |
Interdisciplinary Stem Cell Training Program at UCSD |
$3,684,349 |
|
Sanford-Burnham Medical Research Institute |
Robert Wechsler-Reya |
Research Leadership 1 |
The role of neural stem cells in cerebellar development, regeneration and tumorigenesis |
$5,919,616 |
|
University of Southern California |
Robert Maxson |
Training Grant I-1 |
CIRM Stem Cell Biology Training Grant |
$3,158,532 |
|
University of California, Los Angeles |
Owen Witte |
Training Grant I-1 |
CIRM Type I Comprehensive Training Program |
$3,750,000 |
|
University of California, Davis |
Frederick Meyers |
Training Grant I-1 |
Stem Cell Research Training Grant |
$2,682,900 |
|
University of California, Berkeley |
Randy Schekman |
Training Grant I-1 |
Human Stem Cell Training at UC Berkeley and Childrens Hospital of Oakland |
$2,529,810 |
|
University of California, Irvine |
Peter Bryant |
Training Grant I-1 |
Stem Cell Research Training Grant |
$2,039,845 |
|
Scripps Research Institute |
Peter Schultz |
Training Grant I-2 |
Training Grant I |
$1,059,300 |
|
The J. David Gladstone Institutes |
Robert Mahley |
Training Grant I-2 |
Gladstone CIRM Scholar Program |
$2,397,240 |
|
Sanford-Burnham Medical Research Institute |
Mark Mercola |
Training Grant I-2 |
Burnham Institute CIRM Stem Cell Training Grant (Type II) |
$1,489,640 |
|
University of California, Los Angeles |
Donald Kohn |
Training Grant I-2 |
Training Grant 1 |
$2,390,826 |
|
California Institute of Technology |
Paul Patterson |
Training Grant I-2 |
Training in Stem Cell Biology at CIT |
$2,318,580 |
|
University of California, Santa Barbara |
Dennis Clegg |
Training Grant I-3 |
UCSB Stem Cell Biology Training Program |
$1,343,859 |
|
University of California, Santa Cruz |
David Haussler |
Training Grant I-3 |
Training Program in Systems Biology of Stem Cells |
$1,217,132 |
|
The Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Training Grant I-3 |
Training in the Biology of Human Enbryonic Stem Cells and Emerging Technologies |
$1,496,880 |
|
University of California, Los Angeles |
Kenneth Dorshkind |
Research Training II |
CIRM Research Training Program II |
$7,982,293 |
|
Beckman Research Institute of City of Hope |
Michael Barish |
Research Training II |
Research Training Program in Stem Cell Biology |
$2,500,143 |
|
Stanford University |
Judith Shizuru |
Disease Team Therapy Development - Research |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$20,000,000 |
|
University of California, Los Angeles |
Antoni Ribas |
Disease Team Therapy Development - Research |
Genetic Re-programming of Stem Cells to Fight Cancer |
$19,999,563 |
|
University of California, Davis |
Nancy Lane |
Disease Team Therapy Development - Research |
Treatment of osteoporosis with endogenous Mesenchymal stem cells |
$19,999,867 |
|
University of California, Davis |
John Laird |
Disease Team Therapy Development - Research |
Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia |
$14,184,595 |
|
Children's Hospital of Los Angeles |
David Warburton |
Research Training II |
Stem Cell Training Grant |
$5,103,441 |
|
University of California, Davis |
Vicki Wheelock |
Disease Team Therapy Development - Research |
MSC engineered to produce BDNF for the treatment of Huntington's disease |
$18,950,061 |
|
The J. David Gladstone Institutes |
Robert Mahley |
Research Training II |
CIRM Scholars Program |
$5,111,047 |
|
Cedars-Sinai Medical Center |
Clive Svendsen |
Disease Team Therapy Development - Research |
Progenitor Cells Secreting GDNF for the Treatment of ALS |
$17,842,617 |
|
University of California, Berkeley |
Ellen Robey |
Research Training II |
Interdisciplinary Training in Stem Cell Biology, Engineering and Medicine |
$6,902,189 |
|
StemCells, Inc. |
Alexandra Capela |
Disease Team Therapy Development - Research |
Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy |
$20,000,000 |
|
Scripps Research Institute |
Ulrich Mueller |
Research Training II |
Training Stem Cell Researchers at the Chemistry-Biology Interface |
$4,058,362 |
|
University of California, San Diego |
Karl Willert |
Tools and Technologies II |
Homologous recombination in human pluripotent stem cells using adeno-associated virus. |
$1,993,586 |
|
StemCells, Inc. |
Nobuko Uchida |
Disease Team Therapy Development - Research |
Neural stem cell transplantation for chronic cervical spinal cord injury |
$20,000,000 |
|
University of California, Irvine |
Peter Donovan |
Research Training II |
Research Training Program II |
$6,827,148 |
|
University of California, Irvine |
Henry Klassen |
Disease Team Therapy Development - Research |
Retinal progenitor cells for treatment of retinitis pigmentosa |
$17,306,668 |
|
University of California, San Francisco |
Susan Fisher |
Research Training II |
Training Program in Stem Cell Research |
$7,946,605 |
|
University of California, San Diego |
Sylvia Evans |
Research Training II |
Interdisciplinary Stem Cell Training Program |
$7,890,588 |
|
University of California, Santa Cruz |
David Haussler |
Research Training II |
CIRM Training Program in Systems Biology of Stem cells |
$4,591,616 |
|
The Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Research Training II |
Training in the Biology of Human Embryonic Stem Cells and Emerging Technologies II |
$3,062,677 |
|
Stanford University |
Marius Wernig |
Tools and Technologies II |
Cellular tools to study brain diseases affecting synaptic transmission |
$1,906,494 |
|
University of California, Santa Barbara |
Dennis Clegg |
Research Training II |
Training Program in Stem Cell Biology and Engineering |
$2,451,273 |
|
Stanford University |
Renee Reijo Pera |
Research Training II |
CIRM Training Program |
$7,974,291 |
|
Stanford University |
Joseph Wu |
Disease Team Therapy Development - Research |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$19,999,899 |
|
Buck Institute for Age Research |
David Greenberg |
Research Training II |
CIRM Research Training Program in Stem Cells and Aging |
$3,178,692 |
|
University of Southern California |
Robert Maxson |
Research Training II |
CIRM Stem Cell Biology Training Program |
$6,162,053 |
|
Sanford-Burnham Medical Research Institute |
Mark Mercola |
Research Training II |
Type III CIRM Stem Cell Research Training Program |
$2,856,694 |
|
University of California, Davis |
Frederick Meyers |
Research Training II |
Stem Cell Training Program |
$7,358,024 |
|
Stanford University |
Kenneth Weinberg |
Transplantation Immunology |
“Engineered immune tolerance by Stem Cell-derived thymic regeneration” |
$1,415,836 |
|
Beckman Research Institute of City of Hope |
David DiGiusto |
Early Translational II |
Development of RNA-based approaches to stem cell gene therapy for HIV |
$3,124,130 |
|
University of California, San Diego |
Lawrence Goldstein |
Tools and Technologies II |
Developing a method for rapid identification of high-quality disease specific hIPSC lines |
$1,816,157 |
|
University of California, Los Angeles |
Sophie Deng |
Early Translational II |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$1,654,058 |
|
GMR Epigenetics |
Jifan Hu |
Tools and Technologies II |
Robust generation of induced pluripotent stem cells by a potent set of engineered factors |
$1,452,693 |
|
University of California, Berkeley |
Ellen Robey |
Transplantation Immunology |
Human Immune System Mouse models as preclinical platforms for stem cell derived grafts |
$1,079,393 |
|
University of California, Irvine |
Henry Klassen |
Early Translational II |
Human retinal progenitor cells as candidate therapy for retinitis pigmentosa |
$4,738,251 |
|
University of California, Berkeley |
David Schaffer |
Tools and Technologies II |
Engineering Defined and Scaleable Systems for Dopaminergic Neuron Differentiation of hPSCs |
$1,493,928 |
|
Scripps Research Institute |
Peter Schultz |
Early Translational II |
Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis |
$6,792,660 |
|
University of California, Los Angeles |
Martin Martin |
Tools and Technologies II |
Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders |
$1,783,250 |
|
iPierian, Inc. |
John Dimos |
Early Translational II |
New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells |
$5,665,887 |
|
University of California, Davis |
Roslyn Isseroff |
Early Translational II |
Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds |
$4,526,900 |
|
Gamma Medica-Ideas, Inc. |
James Hugg |
Tools and Technologies II |
Tri-resolution Visualization System for Stem Cells and Tissue Regeneration Monitoring |
$1,528,599 |
|
Children's Hospital of Los Angeles |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$3,607,305 |
|
Stanford University |
Brian Rutt |
Tools and Technologies II |
Development of Single Cell MRI Technology using Genetically-Encoded Iron-Based Reporters |
$1,930,608 |
|
University of California, Los Angeles |
Bruno Peault |
Early Translational II |
Harnessing native fat-residing stem cells for bone regeneration |
$5,391,560 |
|
Stanford University |
Irving Weissman |
Tools and Technologies II |
Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs |
$1,869,487 |
|
University of California, San Diego |
Yang Xu |
Transplantation Immunology |
Induction of immune tolerance to human embryonic stem cell-derived allografts |
$1,193,292 |
|
Cedars-Sinai Medical Center |
Dan Gazit |
Early Translational II |
Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures |
$1,927,698 |
|
University of California, Los Angeles |
Richard Gatti |
Tools and Technologies II |
Use of hiPSCs to develop lead compounds for the treatment of genetic diseases |
$1,833,054 |
|
Stanford University |
Michele Calos |
Early Translational II |
Stem Cell Therapy for Duchenne Muscular Dystrophy |
$2,325,933 |
|
La Jolla Institute for Allergy and Immunology |
Anjana Rao |
Transplantation Immunology |
Generation of regulatory T cells by reprogramming |
$1,503,998 |
|
University of California, Irvine |
leif Havton |
Early Translational II |
Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$1,614,441 |
|
Stanford University |
Sarah Heilshorn |
Tools and Technologies II |
Preparation and Delivery of Clinically Relevant Numbers of Stem Cells Using 3D Hydrogels |
$1,415,981 |
|
University of California, Davis |
William Murphy |
Transplantation Immunology |
Donor natural killer (NK) cells as “veto” cells to promote donor-specific tolerance |
$1,317,569 |
|
The Salk Institute for Biological Studies |
Fred Gage |
Early Translational II |
Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model |
$2,472,839 |
|
The Parkinson's Institute |
J. William Langston |
Tools and Technologies II |
Editing of Parkinson’s disease mutation in patient-derived iPSCs by zinc-finger nucleases
|
$1,327,983 |
|
University of California, San Francisco |
Arturo Alvarez-Buylla |
Early Translational II |
Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy |
$1,752,058 |
|
Cedars-Sinai Medical Center |
Clive Svendsen |
Tools and Technologies II |
Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. |
$1,933,022 |
|
Cedars-Sinai Medical Center |
Terrence Town |
Transplantation Immunology |
Role of HLA in neural stem cell rejection using humanized mice |
$1,472,634 |
|
University of California, Irvine |
Brian Cummings |
Early Translational II |
Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury |
$1,708,549 |
|
Stanford University |
Ricardo Dolmetsch |
Tools and Technologies II |
Development of small molecule screens for autism using patient-derived iPS cells |
$1,884,808 |
|
Beckman Research Institute of City of Hope |
Yanhong Shi |
Early Translational II |
Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell |
$1,731,750 |
|
Stanford University |
Judith Shizuru |
Transplantation Immunology |
Purified allogeneic hematopoietic stem cells as a platform for tolerance induction |
$1,403,557 |
|
Buck Institute for Age Research |
Xianmin Zeng |
Early Translational II |
Banking transplant ready dopaminergic neurons using a scalable process |
$6,016,624 |
|
University of California, Los Angeles |
Stanley Carmichael |
Tools and Technologies II |
Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke
|
$1,825,613 |
|
University of California, Davis |
Mark Zern |
Early Translational II |
Liver Cell Transplantation |
$5,199,767 |
|
University of California, San Francisco |
Daniel Lim |
Tools and Technologies II |
Development and preclinical testing of new devices for cell transplantation to the brain. |
$1,831,723 |
|
University of California, Los Angeles |
Noriyuki Kasahara |
Early Translational II |
Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,370,607 |
|
Fluidigm Corporation |
Marc Unger |
Tools and Technologies II |
Development and Application of Versatile, Automated, Microfluidic Cell Culture System |
$1,943,904 |
|
University of California, San Diego |
Martin Marsala |
Transplantation Immunology |
Induction of immune tolerance after spinal grafting of human ES-derived neural precursors |
$1,387,800 |
|
University of California, San Diego |
Catriona Jamieson |
Early Translational II |
Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,341,758 |
|
Stanford University |
Michele Calos |
Tools and Technologies II |
Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation |
$1,619,627 |
|
Stanford University |
Robert Negrin |
Transplantation Immunology |
Regulatory T cell induced tolerance to ESC transplantation |
$1,427,980 |
|
University of California, Irvine |
Leslie Thompson |
Early Translational II |
A hESc-based Development Candidate for Huntington's Disease |
$3,799,817 |
|
University of California, San Diego |
Shu Chien |
Tools and Technologies II |
Development of Synthetic Microenvironments for Stem Cell Growth and Differentiation |
$1,832,515 |